Matteo Serino

List of Publications by Year in Descending Order

56 papers	5,160 citations	32 h-index	71 g-index
71 ext. papers	6,478 ext. citations	7.9 avg, IF	5.25 L-index

#	Paper	IF	Citations
56	Intestinal gluconeogenesis shapes gut microbiota, fecal and urine metabolome in mice with gastric bypass surgery.. *Scientific Reports*, **2022**, 12, 1415	4.9	1
55	Microbiota medicine: towards clinical revolution.. *Journal of Translational Medicine*, **2022**, 20, 111	8.5	9
54	Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. *Microbiome*, **2021**, 9, 104	16.6	15
53	The Genotoxin Colibactin Shapes Gut Microbiota in Mice. *MSphere*, **2020**, 5,	5	15
52	Evolution of Gut Microbiome and Metabolome in Suspected Necrotizing Enterocolitis: A Case-Control Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
51	Structure function relationships in three lipids A from the Ralstonia genus rising in obese patients. *Biochimie*, **2019**, 159, 72-80	4.6	5
50	A Two-Week Treatment with Plant Extracts Changes Gut Microbiota, Caecum Metabolome, and Markers of Lipid Metabolism in ob/ob Mice. *Molecular Nutrition and Food Research*, **2019**, 63, e1900403	5.9	9
49	SCFAs - the thin microbial metabolic line between good and bad. *Nature Reviews Endocrinology*, **2019**, 15, 318-319	15.2	25
48	Active thrombin produced by the intestinal epithelium controls mucosal biofilms. *Nature Communications*, **2019**, 10, 3224	17.4	22
47	Oral microbiota-induced periodontitis: a new risk factor of metabolic diseases. *Reviews in Endocrine and Metabolic Disorders*, **2019**, 20, 449-459	10.5	29
46	Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections. *Journal of Molecular Biology*, **2018**, 430, 581-590	6.5	14
45	Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity. *Molecular Nutrition and Food Research*, **2018**, 62, 1700721	5.9	46
44	Oral health and microbiota status in professional rugby players: A case-control study. *Journal of Dentistry*, **2018**, 79, 53-60	4.8	9
43	Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. *Nature Medicine*, **2018**, 24, 1070-1080	50.5	276
42	Periodontitis induced by drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. *Gut*, **2017**, 66, 872-885	19.2	107
41	Young microbes for adult obesity. *Pediatric Obesity*, **2017**, 12, e28-e32	4.6	13
40	Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice. *Diabetologia*, **2017**, 60, 690-700	10.3	34

39	Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. *Nature Medicine*, **2017**, 23, 850-858	50.5	732
38	Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism. *Molecular Systems Biology*, **2017**, 13, 921	12.2	32
37	Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice. *American Journal of Physiology - Renal Physiology*, **2016**, 310, G1091-101	5.1	13
36	Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. *Hepatology*, **2016**, 64, 2015-2027	11.2	137
35	Gestational diabetes is associated with changes in placental microbiota and microbiome. *Pediatric Research*, **2016**, 80, 777-784	3.2	72
34	The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORt and Controls Metabolic Disease. *Cell Metabolism*, **2015**, 22, 100-12	24.6	175
33	Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. *EMBO Molecular Medicine*, **2015**, 7, 259-74	12	118
32	Gut Microbiota Interacts With Brain Microstructure and Function. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4505-13	5.6	88
31	Managing the manager: gut microbes, stem cells and metabolism. *Diabetes and Metabolism*, **2014**, 40, 186-90	5.4	12
30	Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. *Current Cardiology Reports*, **2014**, 16, 540	4.2	67
29	Intestinal permeability--a new target for disease prevention and therapy. *BMC Gastroenterology*, **2014**, 14, 189	3	810
28	Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression. *International Journal of Obesity*, **2014**, 38, 737-45	5.5	20
27	A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. *Diabetologia*, **2013**, 56, 2524-37	10.3	75
26	The gut microbiota profile is associated with insulin action in humans. *Acta Diabetologica*, **2013**, 50, 753-61	3.9	39
25	Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. *Molecular Metabolism*, **2013**, 2, 281-91	8.8	66
24	Metagenome and metabolism: the tissue microbiota hypothesis. *Diabetes, Obesity and Metabolism*, **2013**, 15 Suppl 3, 61-70	6.7	77
23	Study of lactoferrin gene expression in human and mouse adipose tissue, human preadipocytes and mouse 3T3-L1 fibroblasts. Association with adipogenic and inflammatory markers. *Journal of Nutritional Biochemistry*, **2013**, 24, 1266-75	6.3	24
22	Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. *International Journal of Obesity*, **2012**, 36, 1442-9	5.5	136

21	High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens. *PLoS ONE*, **2012**, 7, e48220	3.7	49
20	Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. *Gut*, **2012**, 61, 543-53	19.2	415
19	Intestinal MicrobiOMICS to define health and disease in human and mice. *Current Pharmaceutical Biotechnology*, **2012**, 13, 746-58	2.6	32
18	Microbes on-air: gut and tissue microbiota as targets in type 2 diabetes. *Journal of Clinical Gastroenterology*, **2012**, 46 Suppl, S27-8	3	14
17	Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. *Journal of Hepatology*, **2011**, 54, 975-83	13.4	98
16	Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. *PLoS ONE*, **2011**, 6, e20700	3.7	106
15	Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. *Acta Diabetologica*, **2011**, 48, 257-273	3.9	170
14	Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. *Diabetologia*, **2011**, 54, 3055-61	10.3	213
13	Gut microbiota and metabolic diseases: myth or reality?. *Mediterranean Journal of Nutrition and Metabolism*, **2011**, 4, 75-77	1.3	
12	CD14 modulates inflammation-driven insulin resistance. *Diabetes*, **2011**, 60, 2179-86	0.9	78
11	Lipid-induced peroxidation in the intestine is involved in glucose homeostasis imbalance in mice. *PLoS ONE*, **2011**, 6, e21184	3.7	7
10	Gut microbiota and metabolic diseases: myth or reality?. *Mediterranean Journal of Nutrition and Metabolism*, **2010**, 4, 75-77	1.3	
9	The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?. *Frontiers in Bioscience - Landmark*, **2009**, 14, 5107-17	2.8	43
8	Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 831-6	9.4	76
7	A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. *Current Opinion in Pharmacology*, **2009**, 9, 744-52	5.1	37
6	Intestinal microflora and metabolic diseases. *Diabetes and Metabolism*, **2009**, 35, 262-72	5.4	63
5	Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 54-60	4.5	20
4	Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology*, **2009**, 136, 663-72.e4	13.3	90

3	Flore intestinale: de´nouveaux concepts pour la´rgulation du´mEabolisme Eergtique. *Sang Thrombose Vaisseaux*, **2009**, 21, 322-333	3	
2	Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. *Diabetes*, **2007**, 56, 2541-6	0.9	94
1	Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. *Journal of Clinical Investigation*, **2005**, 115, 3494-505	15.9	122